ALK and non-small cell lung carcinoma: Nevertheless, with the recent results from the ADAURA study demonstrating markedly prolonged disease-free survival with adjuvant osimertinib in resected EGFR mutant NSCLC, the enthusiasm for following suit with ALK has mounted, as ADAURA OS data are maturing (133).